Published Date: 13 Mar 2023
Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.
Read Full NewsEli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results in patients with the skin disease and obesity in a...
Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.
Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.
South Carolina reported a surge to 962 measles cases on Tuesday, state health data showed, including 12 additional infections since Friday, as officials warned the widening...
As currently written, the instructions could potentially lead to delayed treatment of high glucose levels.
An expansion of higher-level neonatal care has been observed in urban hospitals in the US over the years, whereas rural hospitals have faced a decline in such care capacity, per a recent study.
1.
FDA Approves New Bladder Cancer First-Line Standard of Care.
2.
UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts
3.
Surgeons are at higher risk of cancer, study suggests
4.
An Eye Surgeon's Unexpected Discovery of the "Before and After".
5.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
1.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
2.
Obesity is a major risk factor for cancer
3.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
4.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
5.
Tazemetostat: A Promising New Treatment for Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation